0469-0125 : Xtandi 40 mg Oral Capsule

Labeler: Astellas Pharma Us, Inc.
Product Type: Human Prescription Drug
Drug Name:  Xtandi
Dosage Form: Oral Capsule
Application #: NDA203415
Rev. Date: 


Markings: MDV
Shapes:  Capsule
Colors:  Black
Size (mm): 12
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

MDV: (0469-0125) Xtandi 40 mg Oral Capsule by Astellas Pharma Us, Inc.
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.

NDC Package Codes:

  • 0469-0125-99: 1 BOTTLE IN 1 CARTON (0469‑0125‑99) > 120 CAPSULE IN 1 BOTTLE

Active Ingredients:

  • Enzalutamide

Dosage Strength:

  • 40 mg

Pharmaceutical Classes:

  • Androgen Receptor Inhibitor [EPC]
  • Androgen Receptor Antagonists [MoA]
  • Cytochrome P450 3A4 Inducers [MoA]
  • Cytochrome P450 2C9 Inducers [MoA]
  • Cytochrome P450 2C19 Inducers [MoA]

Related Products:

Based on records with the same trade name.
  • 0469-0625 Xtandi 40 mg Oral Tablet by Astellas Pharma Us, Inc.
  • 0469-0725 Xtandi 80 mg Oral Tablet by Astellas Pharma Us, Inc.


Scan the QR code below to easily reference this data in the future:

NDC 0469-0125 QR Code

< Prev: 0463-8500Next: 0469-0320 >

Related Discussions:

Can I treat my bone joint stiffness that I have started with Enzalutemide ## Enzalutemide is an androgen receptor agonis... 1 reply
Xtandi and other treatments
My husband has an aggressive form of prostate cancer. In 2 years have been through chemo, radiation, lupron, immunothera... 2 replies

Note: The MedsChat® NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.